Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Strober

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
Microbiome|January 24, 2014
Community differentiation of the cutaneous microbiota in psoriasisAlexander V Alekseyenko, Guillermo I Perez-Perez, Aieska De Souza, et al.
Journal of Drugs in Dermatology : JDD|August 6, 2010
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label studyCraig Leonardi, Bruce Strober, Alice B Gottlieb, et al.
Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.
Dermatology and Therapy|July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area ScoreKim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Rheumatology (Oxford, England)|February 11, 2024
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritisDennis McGonagle, Arthur Kavanaugh, Iain B McInnes, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 8, 2022
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tabletsRichard B Warren, Bruce Strober, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|February 8, 2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind studyAbby S Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al.
The Journal of Clinical and Aesthetic Dermatology|October 23, 2014
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm MeetingNeal Bhatia, Andrew Blauvelt, Marc Brown, et al.
Therapeutic Advances in Musculoskeletal Disease|February 13, 2023
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinibLars E Kristensen, Bruce Strober, Denis Poddubnyy, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
Microbiome|January 24, 2014
Community differentiation of the cutaneous microbiota in psoriasisAlexander V Alekseyenko, Guillermo I Perez-Perez, Aieska De Souza, et al.
Journal of Drugs in Dermatology : JDD|August 6, 2010
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label studyCraig Leonardi, Bruce Strober, Alice B Gottlieb, et al.
Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.
Dermatology and Therapy|July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area ScoreKim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Rheumatology (Oxford, England)|February 11, 2024
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritisDennis McGonagle, Arthur Kavanaugh, Iain B McInnes, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 8, 2022
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tabletsRichard B Warren, Bruce Strober, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|February 8, 2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind studyAbby S Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al.
The Journal of Clinical and Aesthetic Dermatology|October 23, 2014
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm MeetingNeal Bhatia, Andrew Blauvelt, Marc Brown, et al.
Therapeutic Advances in Musculoskeletal Disease|February 13, 2023
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinibLars E Kristensen, Bruce Strober, Denis Poddubnyy, et al.
Pageof 13